Javad Seyedzadeh appointed Senior Vice President of Global Quality Assurance & Regulatory Affairs in Gambro
Press Release • Jan 21, 2008 14:39 GMT
Javad Seyedzadeh brings extensive knowledge and experience from the QA/RA arena having operated for many years globally within the medical and diagnostic industry. Prior to joining Gambro, Javad Seyedzadeh was the Senior Vice President of Siemens Medical Solutions Diagnostics Division, where he was responsible for global Quality Assurance, Regulatory Affairs, Quality Systems, Health Environment and Safety, Reimbursement and Government Affairs, Medical and Clinical Affairs, and Biostatistics.
He also served as a member of the Siemens Medical Solutions Diagnostics Management Group. The Diagnostics Division designs, manufactures and markets Diagnostic systems that touch the lives of five million patients in nearly 100 countries.
Prior to joining Siemens, Javad Seyedzadeh has led the Quality and Regulatory functions at Bayer Diagnostics and Toshiba. Under his leadership, Javad has led the creation of an innovative worldwide quality management system, encompassing over fifteen sites in forty-four countries and enabling the division to achieve an industry leading stature. His efforts furthered the leadership position of these two companies in the healthcare industry and helped create a competitive advantage.
“I am truly very excited about having Javad Seyedzadeh joining our team. His proven leadership, industry and global experience as well as his insights will be invaluable as we continue to further develop Gambro as a leading company in the renal industry, says Thomas Glanzmann, CEO and President of Gambro.
For further information please contact:
Maria Långberg, Vice President, Communications, tel. +46-8-613 6573, +46-70-513 6573
Anne Bonelli, Gambro Americas Director of Marketing Communications, +1 303-231-4671
Gambro is a global medical technology company and a leader in developing, manufacturing and supplying products and therapies for Kidney and Liver dialysis, Myeloma Kidney Therapy, and other extracorporeal therapies for Chronic and Acute patients. Gambro was founded in 1964 and has today 7 500 employees, production facilities in 9 countries, and sales in more than 100 countries.